Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817931 · ClinicalTrials.gov registry record · Phase 4
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
A Phase 4 study of Dementia and Overactive Bladder, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT03817931 is a Phase 4 study of Dementia and Overactive Bladder that has completed, run by Baylor Research Institute. The registered enrollment target is 12 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03817931, a Phase 4 study of Dementia and Overactive Bladder, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.
Conditions Studied
Interventions
- DRUG Anticholinergic
- DRUG Beta-3 Agonists, Adrenergic
- DIAGNOSTIC_TEST Functional magnetic resonance imaging (fMRI)
- DIAGNOSTIC_TEST Rey Auditory Verbal Learning Test (RAVLT)
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Baylor Scott and White Health - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2022-02-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817931
The ClinicalTrials.gov registry entry for NCT03817931 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Dementia appearing as the primary indexed condition, and to 4 interventions - of which Anticholinergic is the first listed.
NCT03817931 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03817931 about?
NCT03817931 is a clinical study titled "Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder". Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded interve...
What is the current status of trial NCT03817931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2019-08-05. Estimated completion is 2022-02-26.
What conditions does trial NCT03817931 study?
This clinical trial studies the following conditions: Dementia, Overactive Bladder, Lower Urinary Tract Symptoms, Incontinence, Urge.
What interventions are being tested in trial NCT03817931?
The interventions under investigation include: Anticholinergic (DRUG), Beta-3 Agonists, Adrenergic (DRUG), Functional magnetic resonance imaging (fMRI) (DIAGNOSTIC_TEST), Rey Auditory Verbal Learning Test (RAVLT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03817931?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817931 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
COMPLETED · Phase 4
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.